Compare CleanSpark Inc (CLSK) vs McKesson Corporation (MCK) Price & Performance

CleanSpark trades at $12.18, up 5.09% today but facing bearish technical signals with 17 sell indicators versus 5 buy signals. The company reported four consecutive quarterly earnings misses, with Q2 2026 showing a loss of $0.89 per share versus expectations of -$0.47. Despite negative profitability metrics including a -146.9% net income margin, analysts maintain unanimous buy ratings with a $24.13 consensus price target, representing 98% upside potential. Recent news highlights a strategic pivot to AI data centers through a $6.6 billion, 20-year lease agreement.

The stock presents a high-risk, high-reward opportunity with strong analyst conviction contrasting weak fundamentals. The AI data center expansion offers significant long-term revenue potential but requires substantial capital investment amid current cash flow challenges. Key risks include execution of the strategic pivot, continued earnings volatility, and the need for additional financing to support growth initiatives.

McKesson (MCK) trades at $877.87, down 0.23% on the day, with strong technical momentum indicated by bullish moving averages and ADX signals. The company reported robust Q1 2027 results with EPS of $9.93 beating estimates by 20% year-over-year, driven by specialty drug growth and oncology performance. Revenue reached $105.4 billion, up 8%, prompting management to raise full-year adjusted EPS guidance. Analyst consensus remains strongly bullish with 24 buy ratings and a $990.67 price target, representing 13% upside potential.

MCK presents a compelling investment case with consistent earnings beats, raised guidance, and strong operational cash flow of $6.9 billion projected for 2026. Key risks include margin pressure from the low 1.12% net income margin, high accounts payable of $55.33 billion, and negative shareholder equity of -$2.07 billion. The stock's valuation at 24.19 P/E appears reasonable given growth prospects, but investors should monitor debt levels and pharmaceutical pricing dynamics.